11th Annual

Fragment-Based Drug Discovery

From Hits to Leads and Lessons Learned

April 20-21, 2016

Fragment-Based Drug Discovery icon  


Fragment-based drug discovery (FBDD) is an approach for finding new drug leads that over the past decade has increasingly been adopted by research departments at biotechnology and pharmaceutical companies. However, rarely is FBDD the only funnel for providing small molecule lead compounds. High throughput screening campaigns on synthetic and natural small molecule libraries represent the more traditional approach to discovering new oral-based therapies and often medicinal chemists are faced with the challenge of using information from both efforts to optimize and develop compounds with the best drug potential.

But with more than thirty compounds in clinical trials and at least one drug on the market whose origins can be traced to fragment-based approaches, there is a wealth of experience and information to be shared for moving the field forward. Join fellow biophysical and medicinal chemists at Cambridge Healthtech’s Fragment-Based Drug Discovery to discuss and debate pitfalls, solutions and best practices in this growing area of drug discovery. This day-and-a-half meeting is in the second half of CHI’s larger Drug Discovery Chemistry event.

Topics may include, but are not limited to:

  • Evolving fragment hits to drug leads – different approaches, case studies
  • Optimizing fragment hits in the absence of crystal structure
  • Approaches for fragment library screening: NMR, 19-F NMR, SPR, DSF and other biophysical techniques
  • How low can you go (in fragment ligand affinity/efficiency)?
  • Concepts in library design (3D, general v. specialized libraries)
  • FBDD for PPIs and membrane proteins
  • FBDD for finding allosteric inhibitors

If you would like to submit a proposal to give a presentation at this meeting, please click here.

The deadline for submission is October 2, 2015

All proposals are subject to review by the Scientific Advisory Committee to ensure the highest quality of the conference program. Please note that due to limited speaking slots, preference is given to pharmaceutical and biotech companies, regulators and those from academia. Additionally, vendors/consultants who provide products and services to these biopharmaceutical companies are offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

For more details on the conference, please contact:
Anjani Shah, Ph.D.
Conference Director Cambridge Healthtech Institute
Phone: (914) 723-0255
Email: ashah@healthtech.com

For partnering & sponsorship information, please contact:
Carolyn Benton
Business Development Manager
Cambridge Healthtech Institute
Phone: (+1) 781-972-5412
Email: cbenton@healthtech.com